Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

SVRA

Savara Inc

Feb 12 • 04:00PM ET

5.83

+0.48 8.97 %

Healthcare • Biotechnology • USA • NASD

Peers: BMRN RARE ARWR NVAX AXSM HRTX ACAD PTGX KPTI CRBP

| Held by: VTI IWM VXF XBI IWO VTWO IBB SCHA LFSC IWC

Index	RUT	P/E	-	EPS (ttm)	-0.54	Insider Own	49.66%	Shs Outstand	172.85M	Perf Week	12.98%
Market Cap	1.19B	Forward P/E	-	EPS next Y	-0.44	Insider Trans	-0.02%	Shs Float	102.42M	Perf Month	-1.52%
Enterprise Value	1.09B	PEG	-	EPS next Q	-0.12	Inst Own	38.99%	Short Float	20.47%	Perf Quarter	34.64%
Income	-115.64M	P/S	-	EPS this Y	-7.26%	Inst Trans	-0.98%	Short Ratio	8.30	Perf Half Y	115.93%
Sales	0.00M	P/B	10.68	EPS next Y	14.54%	ROA	-60.91%	Short Interest	20.96M	Perf YTD	-3.32%
Book/sh	0.55	P/C	9.54	EPS next 5Y	38.07%	ROE	-78.74%	52W High	7.01 -16.77%	Perf Year	112.00%
Cash/sh	0.61	P/FCF	-	EPS past 3/5Y	-14.63% 24.35%	ROIC	-93.14%	52W Low	1.89 208.47%	Perf 3Y	138.93%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.65% 5.99%	Perf 5Y	233.14%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-22.39%	Oper. Margin	-	ATR (14)	0.35	Perf 10Y	-67.42%
Dividend Ex-Date	-	Quick Ratio	7.65	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	54.20	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	7.65	EPS Q/Q	-19.30%	SMA20	2.97%	Beta	0.31	Target Price	10.81
Payout	-	Debt/Eq	0.32	Sales Q/Q	-	SMA50	-2.57%	Rel Volume	1.06	Prev Close	5.35
Employees	59	LT Debt/Eq	0.32	Earnings	Nov 12 AMC	SMA200	49.41%	Avg Volume	2.53M	Price	5.83
IPO	Oct 16, 2000	Option/Short	Yes / Yes	EPS/Sales Surpr.	-5.66% -	Trades		Volume	2,670,330	Change	8.97%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-20-25	Initiated	Wells Fargo	Overweight	$7
Aug-15-25	Upgrade	H.C. Wainwright	Neutral → Buy	$5
May-29-25	Downgrade	H.C. Wainwright	Buy → Neutral	$2
Dec-20-24	Initiated	Wells Fargo	Overweight	$8
Nov-13-24	Downgrade	Evercore ISI	Outperform → In-line	$7 → $5
Feb-15-24	Initiated	JMP Securities	Mkt Outperform	$8
Nov-07-23	Initiated	Guggenheim	Buy	$7
May-16-23	Upgrade	Jefferies	Hold → Buy	$2 → $4
Mar-31-23	Downgrade	Jefferies	Buy → Hold	$2
Mar-16-21	Initiated	Piper Sandler	Overweight	$7
Mar-15-21	Initiated	Oppenheimer	Outperform	$4
Jun-13-19	Reiterated	H.C. Wainwright	Buy	$22 → $6
Jun-13-19	Downgrade	Ladenburg Thalmann	Buy → Neutral	$21 → $3
Jun-13-19	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Aug-13-18	Resumed	ROTH Capital	Neutral	$12
Jan-03-18	Initiated	Ladenburg Thalmann	Buy	$35
Sep-27-17	Resumed	ROTH Capital	Buy	$40
Sep-22-17	Initiated	Jefferies	Buy	$20
Sep-11-17	Initiated	JMP Securities	Mkt Outperform	$20

Show Previous Ratings

Feb-04-26 04:05PM	Savara Announces Participation in Upcoming Investor Healthcare Conferences (Business Wire) -5.30%
Jan-27-26 08:05AM	Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI* (Business Wire)
Jan-16-26 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Jan-08-26 04:05PM	PANTHERx Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI* (Business Wire)
Dec-22-25 08:30AM	Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) (Business Wire) +6.94%
08:05AM	Loading…
Dec-17-25 08:05AM	Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-11-25 08:05AM	Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI* (Business Wire)
Dec-02-25 08:05AM	Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow Nebulizer System (Business Wire)
Dec-01-25 01:23PM	Savara (SVRA) Climbs 27.8% Ahead of 2 Health Conferences (Insider Monkey) -7.15%
Nov-20-25 04:05PM	Savara Announces Participation in Upcoming Investor Healthcare Conferences (Business Wire) +5.35%
Nov-12-25 04:05PM	Savara Reports Third Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Nov-03-25 04:05PM	Savara Announces Participation in Upcoming Investor Healthcare Conferences (Business Wire)
02:56AM	Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA (PR Newswire)
Oct-31-25 04:05PM	Savara Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $149.5M (Business Wire)
Oct-30-25 11:29PM	What Does Wall Street Think About Savara Inc. (SVRA)? (Insider Monkey)
09:43PM	Loading…
Oct-29-25 09:43PM	Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants (Business Wire)
04:07PM	Savara Announces Proposed Public Offering (Business Wire)
04:01PM	Savara announces $75M Royalty Funding Agreement with RTW to Support the Potential Launch of MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) (Business Wire)
11:57AM	Savara Inc. (SVRA) To Present Molgramostim Data in the Fight Against Infections (Insider Monkey)
Oct-17-25 08:05AM	Savara Announces Chief Medical Officer (CMO) Transition (Business Wire)
Oct-13-25 04:59PM	Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA (PR Newswire)
Oct-10-25 09:00AM	Savara Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - SVRA (PR Newswire)
Oct-07-25 07:40AM	Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA (PR Newswire)
Oct-02-25 04:05PM	Savara Announces Encore Presentations of Results From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2025 (Business Wire)
Sep-29-25 02:00AM	Savara Presents New Data From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2025 (Business Wire)
Sep-25-25 04:37PM	Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA (PR Newswire)
Sep-24-25 04:25PM	Did You Lose Money on Savara Inc. (SVRA)? Levi & Korsinsky Urges Investors to Act Before November 7, 2025 (Newsfile)
Sep-23-25 10:53AM	Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights SVRA (Business Wire)
Sep-20-25 02:43AM	Guggenheim Lifts Savara (SVRA) Price Target on Pulmonary Alveolar Proteinosis Opportunity (Insider Monkey)
Sep-11-25 04:18PM	Investors in Savara Inc. (SVRA): Protect Your Rights - Contact Levi & Korsinsky Before November 7, 2025 (Newsfile) -6.27%
09:00AM	Loading…
Sep-02-25 09:00AM	Savara Announces New U.S. Health Claims Data Analysis Finds Over 50% Increase in the Estimated Number of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) Patients Compared to Previous Claims Analysis (Business Wire)
Aug-26-25 04:05PM	Savara Announces Participation in Upcoming Investor Healthcare Conferences (Business Wire) +5.41%
Aug-23-25 04:16AM	Savara Inc. (SVRA) Upgraded to Buy After FDA CMC Breakthrough (Insider Monkey)
Aug-20-25 05:15PM	New England Journal of Medicine (NEJM) to Publish Results From Savara's Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) (Business Wire)
Aug-18-25 08:05AM	Savara to Present New Data from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society Congress 2025 (Business Wire)
Aug-13-25 08:05AM	Savara Reports Second Quarter 2025 Financial Results and Provides a Business Update (Business Wire)
Jul-18-25 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
May-27-25 08:05AM	Savara Receives Refusal to File (RTF) Letter From the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for MOLBREEVI* to Treat Patients With Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP) (Business Wire) -31.69%
07:53AM	Biogen strikes RNAi deal with City; Aurion withdraws IPO (BioPharma Dive)
May-23-25 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
May-22-25 09:05AM	Savara Announces Participation in Jefferies Global Healthcare Conference (Business Wire)
May-21-25 11:16AM	Savara Inc. (SVRA): Analysts See 212% Upside Potential (Insider Monkey) -7.18%
May-18-25 02:30PM	Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at American Thoracic Society Conference (ATS) 2025 (Business Wire)
May-13-25 04:05PM	Savara Reports First Quarter 2025 Financial Results and Provides a Business Update (Business Wire)
May-12-25 04:05PM	Savara Announces Participation in the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference (Business Wire) +5.59%
May-01-25 04:05PM	Savara Announces Participation in the Upcoming Citizens Life Sciences Conference (Business Wire)
Apr-21-25 11:16AM	Savara: Make-It-Or-Break-It Molbreevi BLA Filing (Seeking Alpha)
Apr-11-25 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire) +10.61%
Apr-07-25 04:05PM	Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences (Business Wire) -5.45%
Mar-27-25 07:05AM	Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update (Business Wire)
Mar-26-25 04:45PM	Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital (Business Wire)
04:05PM	Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Mar-17-25 08:05AM	Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025 (Business Wire) +7.66%
Mar-06-25 08:05AM	Savara Announces U.S. Launch of the aPAP ClearPath Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Mar-03-25 04:15PM	Savara Announces Participation in the Leerink Global Healthcare Conference (Business Wire) -6.83%
Feb-14-25 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Jan-30-25 08:39AM	Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research (Business Wire)
Jan-29-25 04:05PM	Savara Announces Participation in Upcoming Healthcare Investor Conferences (Business Wire)
Dec-23-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Dec-18-24 04:05PM	Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire) -6.21% +6.95%
Dec-17-24 04:05PM	Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Nov-22-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
08:05AM	Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024 (Business Wire)
Nov-13-24 01:21PM	Evercore Downgrades Savara on Manufacturing Concerns for Lung Disease Drug Candidate (GuruFocus.com) -15.14%
08:05AM	Savara Announces Participation in Upcoming Healthcare Conferences (Business Wire)
Nov-12-24 08:05AM	Savara Reports Third Quarter 2024 Financial Results and Provides Business Update (Business Wire) -5.90%
Nov-04-24 04:05PM	Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference (Business Wire)
Oct-22-24 08:05AM	Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of The Balancing Act Airing on Lifetime TV (Business Wire)
Oct-18-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire) -5.05%
Oct-01-24 08:05AM	Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting (Business Wire) -5.90%
Sep-27-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
08:05AM	Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Sep-24-24 08:05AM	Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately (Business Wire)
Sep-23-24 08:05AM	Savara to Host Analyst and Investor Webinar on September 30, 2024 (Business Wire)
Sep-08-24 06:45AM	Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024 (Business Wire)
Sep-06-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Sep-03-24 04:05PM	Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Sep-01-24 10:26PM	Savara, Inc. (SVRA): The Best Multibagger Penny Stock of 2025? (Insider Monkey)
Aug-29-24 08:41PM	10 Best Multibagger Penny Stocks of 2025 (Insider Monkey)
Aug-16-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Aug-15-24 08:05AM	Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024 (Business Wire) +5.87%
Aug-12-24 04:05PM	Savara Reports Second Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Jun-29-24 08:35PM	Did Savara Inc. (SVRA) Receive a Good Rating from Wall Street Analysts in Q1? (Insider Monkey)
06:30PM	10 Best Biotech Penny Stocks to Buy Now (Insider Monkey)
Jun-28-24 08:50AM	Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock (Business Wire) +5.77%
Jun-26-24 07:41AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
06:30AM	Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Jun-25-24 08:05PM	Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Jun-19-24 09:00AM	3 Penny Stocks Poised for Major Upside Over the Next 5 Years (InvestorPlace)
Jun-11-24 06:00AM	3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition (InvestorPlace)
May-29-24 08:05AM	Savara to Present at the Jefferies Global Healthcare Conference (Business Wire)
May-21-24 08:20AM	Oppenheimer Adjusts Savara Price Target to $11 From $9.50, Maintains Outperform Rating (MT Newswires)
May-19-24 12:15PM	Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024 (Business Wire)
May-16-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire) -5.08%
May-09-24 10:55PM	SVRA Stock Earnings: Savara Misses EPS for Q1 2024 (InvestorPlace) -8.19%
04:05PM	Savara Reports First Quarter 2024 Financial Results and Provides Business Update (Business Wire)
May-07-24 04:05PM	Savara to Present at the Citizens JMP Life Sciences Conference (Business Wire) +6.26% -5.13%
Apr-08-24 08:05AM	Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024 (Business Wire)
Mar-22-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Mar-07-24 10:54PM	SVRA Stock Earnings: Savara Beats EPS for Q4 2023 (InvestorPlace) -5.19%

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Langhorne, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RAMSAY DAVID A	Director	Dec 19 '25	Sale	6.06	20,000	121,220	2,533,642	Dec 19 05:00 PM
RAMSAY DAVID A	Director	Dec 18 '25	Proposed Sale	6.11	20,000	122,200		Dec 18 11:17 AM
Elam Nevan C	Director	Dec 02 '25	Option Exercise	1.46	5,860	8,556	68,360	Dec 04 06:55 PM
Hawkins Richard J	Director	Nov 14 '25	Option Exercise	1.46	5,860	8,556	121,326	Nov 17 04:38 PM
Hawkins Richard J	Director	Jun 20 '25	Buy	2.04	48,225	98,572	115,466	Jun 23 02:39 PM
McCracken Joseph S	Director	May 29 '25	Buy	2.08	10,000	20,825	260,837	Jun 02 07:59 AM
RAMSAY DAVID A	Director	Mar 31 '25	Buy	2.77	150,000	416,250	2,513,642	Apr 01 07:00 AM

Open in Screener

PSTV

Plus Therapeutics Inc

Feb 12 • 04:00PM ET

0.2570

-0.0142 -5.24 %

Healthcare • Biotechnology • USA • NASD

PSTV Plus Therapeutics Inc daily Stock Chart

Peers: ADAP SUPN KPTI IMUX LITS PBYI CRIS RIGL SYBX

| Held by: VXF

Index	-	P/E	-	EPS (ttm)	-1.90	Insider Own	0.38%	Shs Outstand	178.37M	Perf Week	9.88%
Market Cap	45.84M	Forward P/E	-	EPS next Y	-0.13	Insider Trans	23.73%	Shs Float	177.69M	Perf Month	-45.33%
Enterprise Value	29.26M	PEG	-	EPS next Q	-0.03	Inst Own	11.22%	Short Float	13.54%	Perf Quarter	-54.90%
Income	-24.54M	P/S	8.71	EPS this Y	87.59%	Inst Trans	2.82%	Short Ratio	2.43	Perf Half Y	-55.26%
Sales	5.26M	P/B	6.69	EPS next Y	47.93%	ROA	-191.33%	Short Interest	24.05M	Perf YTD	-49.83%
Book/sh	0.04	P/C	2.76	EPS next 5Y	66.24%	ROE	-	52W High	2.31 -88.87%	Perf Year	-77.05%
Cash/sh	0.09	P/FCF	-	EPS past 3/5Y	47.98% 46.51%	ROIC	-485.48%	52W Low	0.16 57.28%	Perf 3Y	-95.49%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -3.61%	Gross Margin	88.87%	Volatility	10.61% 11.38%	Perf 5Y	-99.53%
Dividend TTM	-	EV/Sales	5.56	EPS Y/Y TTM	22.44%	Oper. Margin	-255.91%	ATR (14)	0.03	Perf 10Y	-100.00%
Dividend Ex-Date	-	Quick Ratio	1.27	Sales Y/Y TTM	-8.16%	Profit Margin	-466.64%	RSI (14)	35.25	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.27	EPS Q/Q	88.74%	SMA20	-0.79%	Beta	0.81	Target Price	5.50
Payout	-	Debt/Eq	0.00	Sales Q/Q	-4.05%	SMA50	-43.10%	Rel Volume	0.38	Prev Close	0.27
Employees	21	LT Debt/Eq	0.00	Earnings	Oct 30 AMC	SMA200	-47.20%	Avg Volume	9.90M	Price	0.26
IPO	Oct 22, 2003	Option/Short	No / Yes	EPS/Sales Surpr.	-100.00% -6.54%	Trades		Volume	3,842,925	Change	-5.24%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-03-26	Initiated	Lake Street	Buy	$2
Sep-03-25	Upgrade	D. Boral Capital	Hold → Buy	$5
Mar-17-25	Initiated	D. Boral Capital	Buy	$9
Jan-25-21	Initiated	Ladenburg Thalmann	Buy	$8
Oct-16-20	Initiated	Maxim Group	Buy	$6

Jan-22-26 07:45AM	Plus Therapeutics Provides Business Update on REYOBIQ Clinical Program and U.S. CNSide Commercialization (GlobeNewswire)
Jan-21-26 04:15PM	Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET (GlobeNewswire)
Jan-14-26 11:36AM	Penny Cancer Stock Plus Therapeutics Raises $15 Million At Discount, Stock Plunges (Benzinga) -38.23%
08:00AM	Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering (GlobeNewswire)
Jan-08-26 07:30AM	Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ for Leptomeningeal Metastases (GlobeNewswire)
07:30AM	Loading…
Dec-11-25 07:30AM	Plus Therapeutics Expands CNSide Assay Platform to State of California (GlobeNewswire) +7.11%
Dec-09-25 07:30AM	Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants (GlobeNewswire) +6.35%
Dec-04-25 07:30AM	Plus Therapeutics Highlights Three REYOBIQ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting (GlobeNewswire) +9.75%
Dec-01-25 07:30AM	Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium (GlobeNewswire)
Nov-24-25 07:30AM	Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ in Leptomeningeal Metastases (GlobeNewswire) +7.98%
Nov-20-25 07:30AM	Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide Cerebrospinal Fluid Assay for Metastatic CNS Cancer (GlobeNewswire)
Nov-17-25 07:30AM	Plus Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement (GlobeNewswire) -7.08%
Nov-06-25 07:30AM	Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.0 (GlobeNewswire) -5.71%
Oct-30-25 06:45PM	Plus Therapeutics (PSTV) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
05:41PM	Plus: Q3 Earnings Snapshot (Associated Press Finance)
04:15PM	Loading…
04:15PM	Plus Therapeutics Reports Third Quarter Financial Results and Recent Business Highlights (GlobeNewswire)
Oct-29-25 07:40AM	United Therapeutics (UTHR) Beats Q3 Earnings Estimates (Zacks) -7.39%
Oct-21-25 07:30AM	Plus Therapeutics Updates on CNSide Diagnostic Platform Launch (GlobeNewswire) +6.94%
Oct-15-25 08:45AM	Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge (PR Newswire)
06:19AM	Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus Therapeutics (Zacks)
Oct-14-25 10:57AM	5 Small Drug Stocks to Buy as the Industry Shows Some Recovery (Zacks)
Sep-26-25 08:07AM	Plus Therapeutics (PSTV) Soars 40% as Firm Seals Partnership with United Healthcare (Insider Monkey) +9.61%
Sep-25-25 07:31AM	Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare For CNS Cancer Diagnostic Kit (Benzinga) +39.29%
07:30AM	Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide Cerebrospinal Fluid Assay for Metastatic CNS Cancer (GlobeNewswire)
Sep-22-25 07:30AM	Plus Therapeutics Announces Additional $1.9 Million Advance Payment from CPRIT (GlobeNewswire)
Sep-18-25 07:30AM	Plus Therapeutics Announces Successful Accreditation and Certification for Its CNSide Diagnostics Clinical Laboratory (GlobeNewswire)
Sep-02-25 04:15PM	Plus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire) -6.27% +7.60%
Aug-26-25 07:30AM	Plus Therapeutics Regains Compliance with Applicable Nasdaq Listing Criteria (GlobeNewswire)
Aug-18-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) -14.62%
07:30AM	Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ in Leptomeningeal Metastases (GlobeNewswire)
07:30AM	Loading…
Aug-15-25 07:30AM	Plus Therapeutics Reports Stockholders' Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements (GlobeNewswire) +15.81%
Aug-14-25 05:30PM	Plus Therapeutics (PSTV) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -5.61%
04:26PM	Plus: Q2 Earnings Snapshot (Associated Press Finance)
04:15PM	Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights (GlobeNewswire)
07:30AM	Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases Conference (GlobeNewswire)
Aug-13-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) -21.40%
Aug-07-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
Aug-06-25 05:35PM	Xencor (XNCR) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +15.47%
Aug-05-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) -10.97%
08:25AM	Ocular Therapeutix (OCUL) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Jul-31-25 07:30AM	Plus Therapeutics Provides US Launch Update for its CNSide Diagnostic (GlobeNewswire) +5.62%
Jul-24-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +21.73%
Jul-23-25 07:30AM	Plus Therapeutics Announces $1.6 Million Advance Payment from CPRIT (GlobeNewswire) +15.29%
Jul-22-25 07:11AM	Leptomeningeal Metastases Market Research Report 2025-2035 \| Competitive Analysis of Plus Therapeutics, AstraZeneca, AngioChem, and Y-mAbs Therapeutics (GlobeNewswire) +10.68%
Jul-15-25 07:30AM	Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ in Patients with Leptomeningeal Metastases (GlobeNewswire) -5.74%
Jul-10-25 07:30AM	Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference (GlobeNewswire)
Jul-08-25 07:30AM	Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ in Leptomeningeal Metastases (GlobeNewswire) +10.88%
Jun-30-25 07:30AM	Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ in Leptomeningeal Metastases (GlobeNewswire) +10.38%
Jun-26-25 08:26AM	FDA approves Plus Therapeutics' Reyobiq for paediatric brain cancer (Pharmaceutical Business Review) +16.38%
07:30AM	Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary (GlobeNewswire)
Jun-25-25 04:15PM	Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, June 26, 2025 at 9:00 A.M. ET (GlobeNewswire) +68.45%
07:30AM	Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer (GlobeNewswire)
Jun-24-25 07:30AM	Plus Therapeutics Announces Comprehensive Restructuring of $15 Million March 2025 Equity Financing (GlobeNewswire)
Jun-19-25 12:00PM	Plus (PSTV) Upgraded to Buy: Here's Why (Zacks)
May-30-25 05:25PM	Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +28.16%
05:20PM	Nutriband Inc. (NTRB) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:15PM	Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights (GlobeNewswire)
May-29-25 05:30PM	The Cooper Companies (COO) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
May-23-25 04:15PM	Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q (GlobeNewswire)
May-15-25 05:40PM	Alpha Cognition Inc. (ACOG) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -17.09%
May-14-25 10:00AM	Plus Therapeutics (PSTV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks) -24.05%
08:15AM	Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Plus Therapeutics' REYOBIQ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM) (GlobeNewswire)
May-12-25 05:10PM	Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +8.74%
May-08-25 08:00AM	Aclaris Therapeutics (ACRS) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +10.01%
07:00AM	Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference (GlobeNewswire)
Apr-24-25 08:56AM	Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics (Zacks) -14.32%
Apr-23-25 09:32AM	5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms (Zacks) +24.97%
08:00AM	Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors (GlobeNewswire)
Apr-15-25 07:30AM	Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (GlobeNewswire)
Apr-01-25 12:00PM	Plus (PSTV) Upgraded to Buy: Here's What You Should Know (Zacks) +7.36%
Mar-28-25 01:12PM	Q4 2024 Plus Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -23.68%
03:04AM	Plus Therapeutics Inc (PSTV) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Mar-27-25 07:42PM	Plus Therapeutics, Inc. (PSTV) Q4 2024 Earnings Call Transcript (SeekingAlpha)
05:35PM	Plus Therapeutics (PSTV) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Mar-21-25 12:17PM	PSTV Stock Surges as FDA Accepts Proprietary Name for Lead Drug (Zacks) -14.49%
06:34AM	Why Plus Therapeutics Inc. (PSTV) Surged On Thursday? (InsiderMonkey)
Mar-20-25 07:30AM	Plus Therapeutics Introduces REYOBIQ , FDA-Accepted Proprietary Name for Lead Drug Candidate (GlobeNewswire) +170.06%
Mar-19-25 07:30AM	Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025 (GlobeNewswire) -8.44%
Mar-11-25 11:00AM	D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement (ACCESSWIRE) +12.60%
Mar-10-25 07:30AM	Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement (GlobeNewswire) -19.11%
Mar-07-25 01:49PM	Why Plus Therapeutics, Inc. (PSTV) Soared on Thursday (Insider Monkey) +9.03%
07:33AM	FDA ODD given to Plus Therapeutics injectable radiotherapy (Pharmaceutical Technology)
07:30AM	Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma (GlobeNewswire)
Mar-06-25 07:30AM	Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer (GlobeNewswire) +311.43%
Mar-05-25 04:01PM	Plus Therapeutics Announces New Employment Inducement Grants (GlobeNewswire) +15.82%
Mar-04-25 02:06PM	Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds (GlobeNewswire) -54.21%
Feb-26-25 07:30AM	Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal Metastases (GlobeNewswire) -29.63%
Feb-24-25 07:30AM	Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary (GlobeNewswire) -5.00%
Feb-20-25 07:30AM	Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer (GlobeNewswire)
Feb-18-25 07:30AM	Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program (GlobeNewswire)
Dec-17-24 07:30AM	Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium (GlobeNewswire) -8.55%
Dec-04-24 07:30AM	Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium (GlobeNewswire)
Dec-03-24 07:30AM	Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply (GlobeNewswire)
Nov-25-24 09:48AM	CNSide Diagnostics reports data from trial of CNSide CSF Assay in LM diagnosis (Medical Device Network)
07:30AM	Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference (GlobeNewswire)
Nov-22-24 07:30AM	Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases (GlobeNewswire)
Nov-21-24 07:30AM	Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases (GlobeNewswire)
Nov-15-24 02:16AM	Plus Therapeutics Inc (PSTV) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ... (GuruFocus.com) -7.14%

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Houston, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HEDRICK MARC H	Chief Executive Officer	Jan 01 '26	Option Exercise	0.00	159,681	0	339,787	Jan 02 04:30 PM
Sims Andrew John Hugh MacIntyr	Chief Financial Officer	Jan 01 '26	Option Exercise	0.00	38,323	0	106,461	Jan 02 04:30 PM
Sims Andrew John Hugh MacIntyr	Chief Financial Officer	Nov 04 '25	Buy	0.51	20,000	10,200	68,138	Nov 05 08:30 AM
HEDRICK MARC H	Chief Executive Officer	Oct 01 '25	Option Exercise	0.00	159,681	0	180,106	Oct 03 04:30 PM
Sims Andrew John Hugh MacIntyr	Chief Financial Officer	Oct 01 '25	Option Exercise	0.00	38,323	0	48,138	Oct 03 04:30 PM
Lenk Robert P	Director	Aug 22 '25	Buy	0.49	110,000	53,779	139,327	Aug 25 07:30 AM
Petersen Greg	Director	May 15 '25	Proposed Sale	0.55	36,666	20,276		May 07 11:59 AM

SVRA

Savara Inc

PSTV

Plus Therapeutics Inc

Upgrade your FINVIZ experience